As funding dipped, early-stage biotechs began tying CEO package components, including salary increases and equity topoffs, to ...
Transitioning from team member to manager has its challenges, including managing ex-peers. There are a few ways you can make ...
Located in BioMidwest, home to manufacturing facilities, biotech, biopharma and medical device companies, Illinois is a hot ...
Amgen on Tuesday secured the FDA’s green light for the first interchangeable biosimilar to AstraZeneca’s Soliris to treat two ...
Driven by growing market demand and an improving supply chain, the global weight-loss drug market is expected to hit $150 ...
In a late-stage trial, Insmed’s small molecule DPP1 inhibitor cut yearly exacerbation rates by around 20% in bronchiectasis ...
As we near the end of second quarter of 2024, the initial public offerings among biotechs have slowed, but the market is ...
The insights AI affords can potentially boost sustainability, but it’s unclear whether these gains outweigh the technology’s ...
AstraZeneca targets $80 billion in revenue by 2030, layoffs at Bayer, BMS and Pfizer continue to generate attention across the biopharma industry, Takeda takes a deep dive into the molecular glue ...
The top 20 biopharma companies by revenue all bring in well over $10 billion dollars annually. Topping the list in 2023 was ...
With back-to-back victories in IgA nephropathy and C3 glomerulopathy, Novartis on Saturday said it is planning to make ...
Until compelling surface targets for lung cancer are developed, antibody-drug conjugates will fail to treat most patients ...